Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy and allergen-specific T and B cell responses in seasonal allergic rhinitis
2012-000594-24Phase 4Terminated
- Sponsor
- Royal Sussex County Hospital
- Start
- Mar 2012
- Modality
- Peptides, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Allergovit Grasses and birch pollen allergoid in allergic rhinitis (AR) (2 arms), sponsored by Royal Sussex County Hospital. Primary endpoint: Modulation of T and B cell responses to pollen allergens by immunotherapy. Started Mar 2012; status: terminated.
02
Drugs
Allergovit Grassesbirch pollen allergoid
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2012-000594-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000594-24.